Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Gleave

Showing results (81-90 of 258) with videos related to

Pageof 26
Sort By:
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 16, 2012
Targeting TCTP as a new therapeutic strategy in castration-resistant prostate cancerVirginie Baylot, Maria Katsogiannou, Claudia Andrieu, et al.
Molecular and Cellular Biology|February 16, 2006
The insulin-like growth factor I receptor is required for Akt activation and suppression of anoikis in cells transformed by the ETV6-NTRK3 chimeric tyrosine kinaseMatthew J Martin, Nataliya Melnyk, Michelle Pollard, et al.
The Prostate|February 19, 2010
Inhibition of DHCR24/seladin-1 impairs cellular homeostasis in prostate cancerMarie-Claude Battista, Marie-Odile Guimond, Claude Roberge, et al.
The Journal of Steroid Biochemistry and Molecular Biology|September 10, 2014
Next-generation steroidogenesis inhibitors, dutasteride and abiraterone, attenuate but still do not eliminate androgen biosynthesis in 22RV1 cells in vitroSteven Pham, Subrata Deb, Dong Sheng Ming, et al.
International Journal of Cancer|August 19, 2014
Hsp27 regulates EGF/β-catenin mediated epithelial to mesenchymal transition in prostate cancerThomas Cordonnier, Jennifer L Bishop, Masaki Shiota, et al.
The Journal of Urology|May 16, 2012
Detection of previously unidentified metastatic disease as a leading cause of screening failure in a phase III trial of zibotentan versus placebo in patients with nonmetastatic, castration resistant prostate cancerEvan Y Yu, Kurt Miller, Joel Nelson, et al.
BMJ Open|August 13, 2021
A phase 3 randomised study of enzalutamide plus leuprolide and enzalutamide monotherapy in high-risk non-metastatic hormone-sensitive prostate cancer with rising PSA after local therapy: EMBARK study designStephen J Freedland, Ugo De Giorgi, Martin Gleave, et al.
Cancer Research|May 19, 2007
DJ-1 binds androgen receptor directly and mediates its activity in hormonally treated prostate cancer cellsJ Erin Tillman, Jialing Yuan, Guangyu Gu, et al.
Molecular Endocrinology (Baltimore, Md.)|August 8, 2014
Crosstalk between nuclear MET and SOX9/β-catenin correlates with castration-resistant prostate cancerYingqiu Xie, Wenfu Lu, Shenji Liu, et al.
Molecular Cancer Research : MCR|October 13, 2023
RNF185 Control of COL3A1 Expression Limits Prostate Cancer Migration and Metastatic PotentialBenjamin Van Espen, Htoo Zarni Oo, Colin Collins, et al.
Pageof 26

Showing results (81-90 of 258) with videos related to

Sort By:
Pageof 26
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 16, 2012
Targeting TCTP as a new therapeutic strategy in castration-resistant prostate cancerVirginie Baylot, Maria Katsogiannou, Claudia Andrieu, et al.
Molecular and Cellular Biology|February 16, 2006
The insulin-like growth factor I receptor is required for Akt activation and suppression of anoikis in cells transformed by the ETV6-NTRK3 chimeric tyrosine kinaseMatthew J Martin, Nataliya Melnyk, Michelle Pollard, et al.
The Prostate|February 19, 2010
Inhibition of DHCR24/seladin-1 impairs cellular homeostasis in prostate cancerMarie-Claude Battista, Marie-Odile Guimond, Claude Roberge, et al.
The Journal of Steroid Biochemistry and Molecular Biology|September 10, 2014
Next-generation steroidogenesis inhibitors, dutasteride and abiraterone, attenuate but still do not eliminate androgen biosynthesis in 22RV1 cells in vitroSteven Pham, Subrata Deb, Dong Sheng Ming, et al.
International Journal of Cancer|August 19, 2014
Hsp27 regulates EGF/β-catenin mediated epithelial to mesenchymal transition in prostate cancerThomas Cordonnier, Jennifer L Bishop, Masaki Shiota, et al.
The Journal of Urology|May 16, 2012
Detection of previously unidentified metastatic disease as a leading cause of screening failure in a phase III trial of zibotentan versus placebo in patients with nonmetastatic, castration resistant prostate cancerEvan Y Yu, Kurt Miller, Joel Nelson, et al.
BMJ Open|August 13, 2021
A phase 3 randomised study of enzalutamide plus leuprolide and enzalutamide monotherapy in high-risk non-metastatic hormone-sensitive prostate cancer with rising PSA after local therapy: EMBARK study designStephen J Freedland, Ugo De Giorgi, Martin Gleave, et al.
Cancer Research|May 19, 2007
DJ-1 binds androgen receptor directly and mediates its activity in hormonally treated prostate cancer cellsJ Erin Tillman, Jialing Yuan, Guangyu Gu, et al.
Molecular Endocrinology (Baltimore, Md.)|August 8, 2014
Crosstalk between nuclear MET and SOX9/β-catenin correlates with castration-resistant prostate cancerYingqiu Xie, Wenfu Lu, Shenji Liu, et al.
Molecular Cancer Research : MCR|October 13, 2023
RNF185 Control of COL3A1 Expression Limits Prostate Cancer Migration and Metastatic PotentialBenjamin Van Espen, Htoo Zarni Oo, Colin Collins, et al.
Pageof 26